The Daily Brief

October 26, 2026

Michigan Republicans are making moves to freeze the state's 24% wholesale marijuana tax for a year. State Representative Jay DeBoyer announced plans to introduce legislation suspending the levy, arguing it has failed to generate the $420 million annually that lawmakers projected when Governor Gretchen Whitmer signed the tax into law in October 2025. Money Collections during the first several months fell substantially short of expectations, and DeBoyer contends the additional financial burden is making it harder for licensed cannabis businesses to compete with unregulated sellers. The proposal differs from other Republican efforts—House Bill 6224 would repeal the tax entirely, and gubernatorial nominee John James has pledged to eliminate or significantly reduce it if elected—but DeBoyer's temporary suspension aims to give legislators time to reassess whether the tax structure itself needs reform.

Context The Michigan case illustrates a broader pattern: cannabis tax projections often rest on assumptions about market behavior that don't hold up once implementation begins. When states layer multiple taxes—Michigan now collects the 24% wholesale levy plus a 10% retail excise tax plus standard 6% sales tax—total effective tax rates climb steeply, and price-sensitive consumers shift toward illegal suppliers. Licensed operators face razor-thin margins, and revenue projections built on legal-market volume become unrealistic almost immediately.

Across the country, voters in Massachusetts are rejecting an attempt to roll back legalization entirely. Ballot Question 8 would repeal the state's adult-use cannabis framework, but polling and reporting from the Cape Cod Times indicates voters do not want to reverse course. Context This reflects a national trend: once voters legalize cannabis, they rarely vote to criminalize it again. The question becomes not whether legalization stays but how to fix implementation—tax rates, licensing, supply chain efficiency—rather than whether to abandon the market altogether.

Meanwhile, a constitutional question is reaching the high court: can the federal government ban gun ownership for cannabis users? The Second Amendment intersection with federal cannabis scheduling remains unresolved, and the case highlights a persistent contradiction in American law. States have legalized cannabis for medical and adult use, but federal law still classifies it as Schedule I, creating legal limbo for lawful state consumers who also own firearms.

On the health front, a study in USA Today linked marijuana legalization to a rise in heart-related hospitalizations, adding to the ongoing public health conversation. The research joins earlier findings that have documented both risks and benefits—seizure reduction, cancer cell suppression, Alzheimer's plaque reduction—and underscores that cannabis, like any substance, carries context-dependent effects. The difference remains stark when compared to alcohol, which causes roughly 95,000 U.S. deaths annually, or prescription opioids, which kill over 16,000 per year. Cannabis has recorded zero overdose deaths in human history. The question for regulators becomes not zero-risk—which doesn't exist for any substance—but proportional response and honest risk assessment.

October 26, 2026

Licensed marijuana retailers are driving down local crime rates and boosting community economies, according to analyses released today that underscore the market displacement effect of legal cannabis businesses. Multiple studies show that regulated dispensaries displace unregulated markets, limit youth access, and deliver measurable improvements to local economies—a pattern that has emerged consistently across jurisdictions with established legal frameworks.

Money The broader cannabis industry is navigating significant corporate consolidation, with the Alberta Securities Commission dismissing a legal challenge by Curaleaf Holdings against Aurora Cannabis' at-the-market stock offering program. The regulatory decision marks a win for Aurora in an escalating hostile takeover dispute. Curaleaf launched its unsolicited acquisition bid in August and raised its offer in October to approximately $5 per Aurora share—$1 in cash plus 0.4013 Curaleaf shares. Aurora's board has unanimously rejected the proposal, arguing that it undervalues the company's cash holdings, EU Good Manufacturing Practice-certified facilities, and established international medical operations. The takeover offer is scheduled to expire December 4, though Aurora's special committee continues evaluating alternatives that could provide greater shareholder value.

Consumer confidence in regulated cannabis is strengthening measurably. A Bloomwell survey found that pharmacy cannabis causes four times less stress than purchasing from illegal markets—a gap that reflects the confidence consumers place in licensed retailers and regulated supply chains. Context As more jurisdictions establish legal frameworks, the quality-of-life benefits extend beyond economics into consumer peace of mind and community safety.

Celebrity investment is also flowing into the medical cannabis sector. Rapper Blade Brown has moved into medical cannabis as an investor in Mamedica, signaling continued mainstream legitimacy and capital formation in the therapeutic cannabis space. These high-profile moves reflect a broader pattern: as legal cannabis markets mature and demonstrate tangible economic and public health benefits, investment and entrepreneurial interest expand accordingly.

October 26, 2026

European Union regulators are moving to standardize hemp cultivation and trade rules across all 27 member states, a significant shift toward creating uniform standards rather than fragmented national policies. The Council of the European Union last week approved a universal hemp framework as part of negotiations on the Common Organisation of the Markets, the EU's agricultural policy structure. The proposal would cover all parts of the hemp plant—including the flower—and allow farmers to monetize hemp beyond traditional fiber production, positioning the crop as more competitive and economically attractive across the bloc.

Money The framework maintains a 0.3% THC threshold while requiring all EU hemp to be grown from varieties registered in the Common Catalogue of Varieties of Agricultural Plant Species. By harmonizing these standards continent-wide, the Council aims to eliminate regulatory inconsistencies that currently create administrative friction and competitive disadvantages for farmers operating across borders. The move recognizes that fragmented hemp rules have created a patchwork market where producers in one member state face different compliance burdens than those in another, raising costs and limiting scale.

Context This regulatory alignment reflects a broader European trend: while some U.S. states continue to ban or restrict hemp-derived THC products—including smokable flower—the EU is moving in the opposite direction, expanding the plant's permitted uses and simplifying market access. The union's approach treats hemp as an agricultural commodity with legitimate economic value rather than a threat, and the standardized 0.3% THC ceiling provides public health guardrails without eliminating the plant's commercial potential.

The timing matters. As Willie Nelson's $200 million hemp-based THC drinks brand faces federal pressure in the United States, and Texas operators grapple with bans on smokable hemp products, the EU's move to broaden hemp cultivation opportunities and protect farmer revenue through standardized rules signals a diverging regulatory philosophy. The proposal still requires approval from the European Parliament, but the Council's support suggests momentum toward treating hemp as a normalized agricultural sector rather than a controlled substance.

October 26, 2026

Researchers at the University of Florence have developed a breakthrough CBD eye treatment that significantly reduces intraocular pressure in animal models, offering a potential therapeutic pathway for glaucoma management. The study, accepted for publication this month in the International Journal of Biological Macromolecules, combined CBD-loaded nanoparticles coated with chitosan—a naturally derived compound that adheres to biological surfaces—with a temperature-sensitive gel that liquefies at room temperature but solidifies within 15 seconds on the eye's surface. In rabbits with normal eye pressure, a single 15-microgram application reduced average intraocular pressure from 19.4 mmHg to 17.2 mmHg after 60 minutes, a statistically significant reduction (p<0.0001). In animals with experimentally induced elevated pressure, the CBD formulation outperformed identical treatments without CBD, producing an additional 1.9 mmHg reduction after two hours. Notable Safety testing showed no observable irritation to the cornea, conjunctiva, or iris after five consecutive daily applications, with laboratory studies using human corneal cells supporting short-term tolerability.

Elevated intraocular pressure is a major risk factor for glaucoma, a progressive disease that damages the optic nerve and can cause irreversible vision loss. Current treatments focus on reducing eye pressure to slow disease progression, making these findings potentially relevant to future ophthalmologic therapies. The researchers emphasized that additional clinical studies are necessary to evaluate the treatment's efficacy in human patients before moving toward potential clinical applications.

Beyond ophthalmology, emerging research continues to document cannabinoid effects across multiple physiological systems. A Polish study has found CBD beneficial for post-exercise recovery, while separate research indicates that CBD alters prostate cancer cells and enhances the effects of targeted and hormonal treatments. Recent neuroscience research published this week reveals that endogenous cannabinoid levels—the body's own cannabis-like chemicals—rise continuously during endurance exercise, remaining elevated all the way to the marathon finish line, offering a potential mechanistic explanation for the "runner's high" phenomenon.

The pipeline of medical cannabis clinical trials is expanding across multiple therapeutic areas. Upcoming 2026 trials are monitoring cannabinoid efficacy for conditions ranging from endometriosis to chronic back pain, reflecting a broader shift in clinical research toward understanding cannabis as a plant with measurable therapeutic applications. Context This represents a significant change in research momentum—five years ago, cannabinoid clinical trials numbered in the dozens; today, they span dozens of conditions and involve institutions across North America and Europe.

However, not all cannabinoid research has yielded positive results. Recent research has raised concerns over popular cannabinol sleep supplements, suggesting that marketed claims may outpace current evidence. The divergence between rigorous positive findings (CBD for eye pressure, prostate cancer, exercise recovery) and preliminary or cautionary findings (cannabinol sleep supplements) reflects the broader pattern in cannabis science: specific cannabinoid formulations, dosages, and delivery mechanisms matter significantly, and the plant's complexity resists one-size-fits-all conclusions. As the research base expands, the distinction between rigorous clinical evidence and consumer marketing claims will likely become increasingly important for regulatory bodies and consumers alike.